Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Goserelin Acetate

FDA-approved product (implant, implantation), marketed as Zoladex.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Goserelin Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Gonadotropin releasing hormone analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli58.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Goserelin Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Goserelin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer

    NCT00669162 · start 2012-08

    Registered record
    Registry ID
    NCT00669162
    Conditions
    Prostate Cancer
    Interventions
    Docetaxel; Radiation Therapy; Casodex and Zoladex (or Lupron)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2012-08
    Completion
    2017-04
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDocetaxel; Radiation Therapy; Casodex and Zoladex (or Lupron)
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • GP Extended Action Triptorelin

    NCT01673984 · start 2012-08

    Registered record
    Registry ID
    NCT01673984
    Conditions
    Prostate Cancer
    Interventions
    Decapeptyl® SR 22.5mg; Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2012-08
    Completion
    2014-02
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDecapeptyl® SR 22.5mg; Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg
    PhasePhase 4
    Registry statusTerminated

  • Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

    NCT01492972 · start 2012-01

    Registered record
    Registry ID
    NCT01492972
    Conditions
    Prostate Cancer
    Interventions
    Radiation; Androgen Suppression Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2012-01
    Completion
    Not recorded
    Enrolment
    192

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionRadiation; Androgen Suppression Therapy
    PhasePhase 3
    Registry statusRecruiting

  • Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin

    NCT01738724 · start 2012-01

    Registered record
    Registry ID
    NCT01738724
    Conditions
    Uterine Leiomyoma
    Interventions
    Dienogest; Goserelin; Desogestrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2012-01
    Completion
    2017-12
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUterine Leiomyoma
    InterventionDienogest; Goserelin; Desogestrel
    PhasePhase 4
    Registry statusTerminated

  • Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer

    NCT01368263 · start 2011-09

    Registered record
    Registry ID
    NCT01368263
    Conditions
    Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
    Interventions
    goserelin acetate; letrozole; anastrozole; chemotherapy; Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-09
    Completion
    2013-05
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEstrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer +2 more
    Interventiongoserelin acetate; letrozole; anastrozole; chemotherapy +1 more
    PhasePhase 2
    Registry statusTerminated

  • Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy

    NCT01280045 · start 2011-01

    Registered record
    Registry ID
    NCT01280045
    Conditions
    UTERINE LEIOMYOMA
    Interventions
    VAGINAL HYSTERECTOMY
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2011-01
    Completion
    2015-01
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUTERINE LEIOMYOMA
    InterventionVAGINAL HYSTERECTOMY
    PhaseNot applicable
    Registry statusTerminated

  • Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

    NCT00833248 · start 2009-04

    Registered record
    Registry ID
    NCT00833248
    Conditions
    Prostate Cancer
    Interventions
    Degarelix; Goserelin; Bicalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-04
    Completion
    2011-09
    Enrolment
    246

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDegarelix; Goserelin; Bicalutamide
    PhasePhase 3
    Registry statusCompleted

  • Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer

    NCT00769795 · start 2008-10

    Registered record
    Registry ID
    NCT00769795
    Conditions
    Prostate Cancer
    Interventions
    IMC-A12; Bicalutamide; Goserelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-10
    Completion
    2011-11
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionIMC-A12; Bicalutamide; Goserelin
    PhasePhase 2
    Registry statusCompleted

  • Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

    NCT00567580 · start 2008-02

    Registered record
    Registry ID
    NCT00567580
    Conditions
    Prostate Cancer
    Interventions
    PBRT; PLNRT; AA; LHRH agonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2008-02
    Completion
    Not recorded
    Enrolment
    1,792

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionPBRT; PLNRT; AA; LHRH agonist
    PhasePhase 3
    Registry statusUnknown

  • Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

    NCT00589472 · start 2007-11

    Registered record
    Registry ID
    NCT00589472
    Conditions
    Prostate Adenocarcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer
    Interventions
    Bicalutamide; Goserelin Acetate; Laboratory Biomarker Analysis; Leuprolide Acetate; Therapeutic Conventional Surgery; Vorinostat
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-11
    Completion
    2010-06
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer +1 more
    InterventionBicalutamide; Goserelin Acetate; Laboratory Biomarker Analysis; Leuprolide Acetate +2 more
    PhasePhase 2
    Registry statusCompleted

  • Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women

    NCT00322348 · start 2006-04

    Registered record
    Registry ID
    NCT00322348
    Conditions
    Advanced Breast Cancer
    Interventions
    Goserelin acetate; Goserelin acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-04
    Completion
    2009-11
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer
    InterventionGoserelin acetate; Goserelin acetate
    PhasePhase 2
    Registry statusCompleted

  • Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

    NCT00500110 · start 2003-06

    Registered record
    Registry ID
    NCT00500110
    Conditions
    Prostate Cancer
    Interventions
    Docetaxel; Imatinib Mesylate; Leuprolide; Goserelin Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-06
    Completion
    2010-02
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDocetaxel; Imatinib Mesylate; Leuprolide; Goserelin Acetate
    PhasePhase 2
    Registry statusCompleted

  • Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex

    NCT00235937 · start 2001-12

    Registered record
    Registry ID
    NCT00235937
    Conditions
    Breast Cancer
    Interventions
    Anastrozole and goserelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-12
    Completion
    2006-12
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionAnastrozole and goserelin
    PhasePhase 2
    Registry statusCompleted

  • Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

    NCT00586898 · start 2001-07

    Registered record
    Registry ID
    NCT00586898
    Conditions
    Prostate; Cancer; Hormonal Cycling
    Interventions
    GnRH; Ketoconazole; Bicalutamide; Testosterone transdermal gel; Estrogen transdermal patch
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-07
    Completion
    2009-03
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate; Cancer; Hormonal Cycling
    InterventionGnRH; Ketoconazole; Bicalutamide; Testosterone transdermal gel +1 more
    PhasePhase 2
    Registry statusCompleted

  • Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone

    NCT00223145 · start 2000-12

    Registered record
    Registry ID
    NCT00223145
    Conditions
    Prostate Cancer
    Interventions
    Radiotherapy 70 Gy; Radiotherapy 76 Gy; Androgen blockade
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2000-12
    Completion
    2027-12-31
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionRadiotherapy 70 Gy; Radiotherapy 76 Gy; Androgen blockade
    PhasePhase 3
    Registry statusActive not recruiting